3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
1
Endocrine
1
Conditions
Pathologic Complete Response
1
Colorectal Neoplasms
1
Carcinoma, Neuroendocrine
1
Interventions
pembrolizumab
589
Cyclophosphamide
539
Magnetic Resonance Spectroscopy
523
Radiotherapy
506
Specimen Handling
503
Nivolumab
407
Cisplatin
370
Carboplatin
358
Biopsy
304
Blood Specimen Collection
295
Radiosurgery
283
Paclitaxel
274
Surveys and Questionnaires
268
Standard of Care
266
Gemcitabine
265
fludarabine
261
Dexamethasone
258
Drug Therapy
256
venetoclax
246
Bevacizumab
246
Oxaliplatin
206
Rituximab
195
Capecitabine
194
Radiation
189
Fluorouracil
186
Ipilimumab
184
durvalumab
180
Doxorubicin
175
atezolizumab
172
Etoposide
171
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
OTHER
×
FOLFOXIRI protocol
×
1 year
×
Clear all
NCT02350530
2026-05-22
FORBES
Sun Yat-sen University
Phase 2
Completed
138 enrolled
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled
NCT04325425
2025-09-30
FOLFIRINEC
Centre Hospitalier Universitaire Dijon
Phase 2
Recruiting
218 enrolled